Bayer: Nexavar Boosts Overall Survival In Liver-Cancer Trial (Asia)
This article was originally published in PharmAsia News
Executive Summary
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals Inc. report the drug Nexavar significantly improved overall survival rates in a Phase 3 Asia-Pacific regional trial of the drug. The drug also improved progression-free survival and time to progression among patients with advanced hepatocellular carcinoma, the most common type of liver cancer. The companies say the trial will end early to allow all patients to receive treatment with Nexavar. (Click here for more - May Require Paid Subscription